An effect of ATM variants on the radio-sensitivity of gliomas was previously reported, with significantly higher 1-year in-field control rates after radiation therapy in IDH-wildtype high-grade gliomas with versus without somatic pathogenic ATM variants [35]. This evidence concerns the gene ATM and central nervous system cancer.